|
|
|
20.06.25 - 19:12
|
In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities (Business Wire)
|
|
|
Risk of insolvency as early as end of June 2025
Launch of a donation campaign open to all via the onparticipe.fr online platform
To listen to CARMAT CEO's message,
click herePARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces the launch of a donation campaign open to all, to help fund its operations and continue its mission.
Critical financial situation and risk of insolvency at the end of June 2025
In a separate press release published today (see the press release), CARMAT announced that it is currently in a critical financial situation and facing a risk of insolvency as early as the end of June 2025.
The Company estimates its 12-month financial needs at approximately €35 million, including €3.5 million needed urgently before the end of June 2025, ...
|
|
|
09.04.25 - 17:51
|
CARMAT Delivers Q1 2025 Results in Line With Its Objectives (Business Wire)
|
|
|
Quarterly sales of €2.4m - multiplied by 2.4 vs Q1 2024
EFICAS clinical trial - recruitment 94% complete
2 scientific publications - a strong driver of Aeson® adoption
Final stage of discussions with the FDA with a view to resume the EFS study in the United States shortly
PARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (Paris:ALCAR):
Videoconference in English and French this evening.
To join, please register by clicking on one of the following links:
Videoconference in French at 6:00 pm CEST
-
Videoconference in English at 8:00 pm CEST
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today presents its achievements for the first quarter of 2025 and outlook.
Stéphane Piat, Chief Executive Officer of CARMAT, stated: "We have delivered a solid first quarter, in line with our objectives.
The beginning...
|
|
|
27.03.25 - 07:06
|
CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment (Business Wire)
|
|
|
PARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), announces the implementation of a flexible equity financing line with IRIS Capital Investment (“IRIS”), for a maximum of 9,000,000 shares (i.e., approximately 15% of its current share capital), over a 24-month period.
Stéphane Piat, Chief Executive Officer of CARMAT, comments: "I am very pleased with the implementation of this financing line with IRIS Capital Investment, which, based on our current share price, provides us with a potential total financing amount of approximately €7.9 million over the next 24 months, and thus offers substantial room for manoeuvre that we can start benefitting from immediately. In parallel, we are actively working on securing additional funding to ensure the long-term develop...
|
|
|
29.01.25 - 18:03
|
CARMAT: 2025 Financial Calendar (Business Wire)
|
|
|
PARIS--(BUSINESS WIRE)--$carmat #alcar--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces its indicative financial calendar for 2025.
This preliminary agenda may be modified. Each publication will be released before market opening.
Event
Date
2024 Full-Year Results
Tuesday, April 29, 2025
Shareholders' Meeting
Thursday, June 26, 2025
2025 Half-Year Results
Wednesday, September 10, 2025
***
About CARMAT
CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company's ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The wo...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
